Amgen 2011 Annual Report Download - page 117

Download and view the complete annual report

Please find page 117 of the 2011 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 184

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • 181
  • 182
  • 183
  • 184

Exhibit No. Description
10.29 Product License Agreement, dated September 30, 1985, and Technology License Agreement,
dated September 30, 1985, between Kirin-Amgen, Inc. and Ortho Pharmaceutical Corporation.
(Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2000 on August 1, 2000 and
incorporated herein by reference.)
10.30 Research, Development Technology Disclosure and License Agreement: PPO, dated January 20,
1986, by and between Kirin Brewery Co., Ltd. and Amgen Inc. (Filed as an exhibit to Amendment
No. 1 to Form S-1 Registration Statement on March 11, 1986 and incorporated herein by
reference.)
10.31 Assignment and License Agreement, dated October 16, 1986 (effective July 1, 1986, between
Amgen and Kirin-Amgen, Inc. (Filed as an exhibit to Form 10-K for the year ended December 31,
2000 on March 7, 2001 and incorporated herein by reference.)
10.32 G-CSF United States License Agreement, dated June 1, 1987 (effective July 1, 1986), Amendment
No. 1, dated October 20, 1988, and Amendment No. 2, dated October 17, 1991 (effective
November 13, 1990), between Kirin-Amgen, Inc. and Amgen Inc. (Filed as exhibits to Form 10-K
for the year ended December 31, 2000 on March 7, 2001 and incorporated herein by reference.)
10.33 G-CSF European License Agreement, dated December 30, 1986, between Kirin-Amgen and
Amgen, Amendment No. 1 to Kirin-Amgen, Inc. / Amgen G-CSF European License Agreement,
dated June 1, 1987, Amendment No. 2 to Kirin-Amgen, Inc. / Amgen G-CSF European License
Agreement, dated March 15, 1998, Amendment No. 3 to Kirin-Amgen, Inc. / Amgen G-CSF
European License Agreement, dated October 20, 1988, and Amendment No. 4 to Kirin-Amgen,
Inc. / Amgen G-CSF European License Agreement, dated December 29, 1989, between Kirin-
Amgen, Inc. and Amgen Inc. (Filed as exhibits to Form 10-K for the year ended December 31,
2000 on March 7, 2001 and incorporated herein by reference.)
10.34 Agreement Regarding Governance and Commercial Matters, dated December 16, 2001, by and
among American Home Products Corporation, American Cyanamid Company and Amgen Inc.
(with certain confidential information deleted therefrom). (Filed as an exhibit to Amendment No.
1 to Form S-4 Registration Statement on March 22, 2002 and incorporated herein by reference.)
10.35 Amended and Restated Promotion Agreement, dated as of December 16, 2001, by and among
Immunex Corporation, American Home Products Corporation and Amgen Inc. (with certain
confidential information deleted therefrom). (Filed as an exhibit to Amendment No. 1 to Form S-4
Registration Statement on March 22, 2002 and incorporated herein by reference.)
10.36 Description of Amendment No. 1 to Amended and Restated Promotion Agreement, effective as of
July 8, 2003, among Wyeth, Amgen Inc. and Immunex Corporation (with certain confidential
information deleted therefrom). (Filed as an exhibit to Form 10-K for the year ended December
31, 2003 on March 11, 2004 and incorporated herein by reference.)
10.37 Description of Amendment No. 2 to Amended and Restated Promotion Agreement, effective as of
April 20, 2004, by and among Wyeth, Amgen Inc. and Immunex Corporation. (Filed as an exhibit
to Form S-4/A on June 29, 2004 and incorporated herein by reference.)
10.38 Amendment No. 3 to Amended and Restated Promotion Agreement, effective as of January 1,
2005, by and among Wyeth, Amgen Inc. and Immunex Corporation (with certain confidential
information deleted therefrom). (Filed as an exhibit to Form 10-Q for the quarter ended March 31,
2005 on May 4, 2005 and incorporated herein by reference.)
10.39 Confirmation of OTC Convertible Note Hedge related to 2013 Notes, dated February 14, 2006, to
Amgen Inc. from Merrill Lynch International related to 0.375% Convertible Senior Notes Due
2013. (Filed as an exhibit to Form 10-K for the year ended December 31, 2005 on March 10, 2006
and incorporated herein by reference.)
10.40 Confirmation of OTC Warrant Transaction, dated February 14, 2006, to Amgen Inc. from Merrill
Lynch International for warrants expiring in 2013. (Filed as an exhibit to Form 10-K for the year
ended December 31, 2005 on March 10, 2006 and incorporated herein by reference.)
101